Research Summaries

The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...

The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.

A systematic review and meta-analysis evaluated whether pharmacist-led deprescribing interventions reduce polypharmacy and potentially inappropriate medications among older adults across care settings. ...

This AAEM26 session examined a multihospital program, highlighting teletriage, virtual ED care, and more.

A stepped-wedge cluster randomized trial evaluated whether pairing electronic decision support with routine medication reviews increases deprescribing of potentially inappropriate medications among older...

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

This AAEM26 session reviewed recent evidence challenging traditional approaches to common orthopedic injuries.

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

Long-term data clarify recurrence and surgery rates after antibiotic treatment for uncomplicated appendicitis in adults.

Post hoc subgroup analysis of interim phase 3 data shows weight loss with atogepant in migraine and overweight or obesity.